A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

Abstract Background Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) o...

Полное описание

Библиографические подробности

Главные авторы:	Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, Shengyun Liu, Huaxiang Liu, Malgorzata Miakisz, Jieruo Gu, Lali Kilasonia, Mykola Stanislavchuk, Xiaolei Yang, Yinbo Zhou, Qingfeng Dong, Marian Mitroiu, Janet Addison, Mourad F. Rezk, Xiaofeng Zeng
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2024-09-01
Серии:	Arthritis Research & Therapy
Предметы:	Rheumatoid arthritis Biosimilar pharmaceuticals Tocilizumab Treatment switching
Online-ссылка:	https://doi.org/10.1186/s13075-024-03375-w
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!